Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ITGB1 | P05556 | 5/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CCR1 | P32246 | 2/20 | 0.40 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2196156 | 0.91 | HCRTR1 (0.51) | HCRTR1HCRTR2KMT2ASMN1; SMN2ITGB1 | |
| SCHEMBL2198719 | 0.88 | HCRTR1 (0.48) | HCRTR1HCRTR2KMT2ASMN1; SMN2ITGB1 | |
| SCHEMBL2190466 | 0.87 | HCRTR1 (0.47) | HCRTR1HCRTR2KMT2ASMN1; SMN2ITGB1 | |
| SCHEMBL2194705 | 0.87 | HCRTR1 (0.47) | HCRTR1HCRTR2KMT2ASMN1; SMN2ITGB1 | |
| SCHEMBL2192120 | 0.85 | ALDH1A1 (0.47) | HCRTR1HCRTR2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2199176 | 0.84 | HCRTR1 (0.45) | HCRTR1HCRTR2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2199180 | 0.84 | HCRTR1 (0.45) | HCRTR1HCRTR2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13570511 | 0.84 | HCRTR1 (0.45) | HCRTR1HCRTR2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13571673 | 0.83 | ALDH1A1 (0.47) | HCRTR1HCRTR2KMT2ASMN1; SMN2ALDH1A1 | |
| SCHEMBL13570490 | 0.83 | HCRTR1 (0.43) | HCRTR1HCRTR2KMT2ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362020-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | claimed |
| EP-2519506-A1 | HEPATITIS C VIRUS INHIBITORS | Bristol-Myers Squibb Company (US) | 2012-11-07 | — | — | EP | claimed |
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-01 | — | — | US | claimed |
| WO-2011082077-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-07-07 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294819-A1 | Hepatitis C Virus Inhibitors | HAVCR2, MAVS, GTF3C1 | HCRTR1 4731/4885HCRTR2 4822/4885KMT2A 3866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.